- Home
- LNSR vs ATOS Comparison
LNSR vs ATOS Comparison
Compare LNSR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNSR
- ATOS
- Stock Information
- Founded
- LNSR 2004
- ATOS 2009
- Country
- LNSR United States
- ATOS United States
- Employees
- LNSR N/A
- ATOS N/A
- Industry
- LNSR Medical Electronics
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- LNSR Health Care
- ATOS Health Care
- Exchange
- LNSR Nasdaq
- ATOS Nasdaq
- Market Cap
- LNSR 142.0M
- ATOS 120.4M
- IPO Year
- LNSR N/A
- ATOS 2012
- Fundamental
- Price
- LNSR $12.16
- ATOS $0.85
- Analyst Decision
- LNSR Hold
- ATOS Strong Buy
- Analyst Count
- LNSR 1
- ATOS 3
- Target Price
- LNSR $15.00
- ATOS $6.25
- AVG Volume (30 Days)
- LNSR 44.6K
- ATOS 1.2M
- Earning Date
- LNSR 11-06-2025
- ATOS 11-12-2025
- Dividend Yield
- LNSR N/A
- ATOS N/A
- EPS Growth
- LNSR N/A
- ATOS N/A
- EPS
- LNSR N/A
- ATOS N/A
- Revenue
- LNSR $58,364,000.00
- ATOS N/A
- Revenue This Year
- LNSR $30.80
- ATOS N/A
- Revenue Next Year
- LNSR $33.09
- ATOS N/A
- P/E Ratio
- LNSR N/A
- ATOS N/A
- Revenue Growth
- LNSR 29.34
- ATOS N/A
- 52 Week Low
- LNSR $5.52
- ATOS $0.55
- 52 Week High
- LNSR $17.31
- ATOS $1.66
- Technical
- Relative Strength Index (RSI)
- LNSR 50.62
- ATOS 38.24
- Support Level
- LNSR $11.85
- ATOS $0.86
- Resistance Level
- LNSR $12.69
- ATOS $0.91
- Average True Range (ATR)
- LNSR 0.28
- ATOS 0.05
- MACD
- LNSR 0.05
- ATOS -0.02
- Stochastic Oscillator
- LNSR 50.93
- ATOS 3.08
About LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.